Movatterモバイル変換


[0]ホーム

URL:


SG11202100746WA - Anti-tigit antibody and use thereof - Google Patents

Anti-tigit antibody and use thereof

Info

Publication number
SG11202100746WA
SG11202100746WASG11202100746WASG11202100746WASG11202100746WASG 11202100746W ASG11202100746W ASG 11202100746WASG 11202100746W ASG11202100746W ASG 11202100746WASG 11202100746W ASG11202100746W ASG 11202100746WASG 11202100746W ASG11202100746W ASG 11202100746WA
Authority
SG
Singapore
Prior art keywords
tigit antibody
tigit
antibody
Prior art date
Application number
SG11202100746WA
Inventor
Xinzhen Shi
Pan Zhang
Junjian Liu
Original Assignee
Innovent Biologics Suzhou Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innovent Biologics Suzhou Co LtdfiledCriticalInnovent Biologics Suzhou Co Ltd
Publication of SG11202100746WApublicationCriticalpatent/SG11202100746WA/en

Links

Classifications

Landscapes

SG11202100746WA2018-07-252019-07-25Anti-tigit antibody and use thereofSG11202100746WA (en)

Applications Claiming Priority (2)

Application NumberPriority DateFiling DateTitle
CN2018108235832018-07-25
PCT/CN2019/097665WO2020020281A1 (en)2018-07-252019-07-25Anti-tigit antibody and uses thereof

Publications (1)

Publication NumberPublication Date
SG11202100746WAtrue SG11202100746WA (en)2021-03-30

Family

ID=69181312

Family Applications (1)

Application NumberTitlePriority DateFiling Date
SG11202100746WASG11202100746WA (en)2018-07-252019-07-25Anti-tigit antibody and use thereof

Country Status (12)

CountryLink
US (1)US11370837B2 (en)
EP (1)EP3838289A4 (en)
JP (2)JP7524065B2 (en)
KR (1)KR20210040827A (en)
CN (1)CN112135626B (en)
AU (1)AU2019310803B2 (en)
BR (1)BR112021001201A2 (en)
CA (1)CA3092456C (en)
SG (1)SG11202100746WA (en)
TW (1)TWI754157B (en)
WO (1)WO2020020281A1 (en)
ZA (1)ZA202100676B (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US20230057899A1 (en)2019-12-052023-02-23Compugen Ltd.Anti-pvrig and anti-tigit antibodies for enhanced nk-cell based tumor killing
US20230080706A1 (en)*2020-01-212023-03-16Innovent Biologics (Suzhou) Co., Ltd.Recombinant fully human anti-tigit monoclonal antibody formulation, method for preparing same and use thereof
CN111995681B (en)*2020-05-092022-03-08华博生物医药技术(上海)有限公司anti-TIGIT antibody, preparation method and application thereof
CR20220611A (en)2020-06-022023-06-07Arcus Biosciences Inc ANTI-TIGIT ANTIBODIES
KR20230024368A (en)2020-06-182023-02-20제넨테크, 인크. Treatment with anti-TIGIT antibodies and PD-1 axis binding antagonists
TW202216778A (en)2020-07-152022-05-01美商安進公司Tigit and cd112r blockade
WO2022063100A1 (en)*2020-09-222022-03-31南京圣和药业股份有限公司Anti-tigit antibody and double antibody and their application
CN114539405B (en)*2020-11-232024-02-23广东菲鹏制药股份有限公司anti-TIGIT antibodies or antigen-binding fragments thereof
KR20220082776A (en)*2020-12-102022-06-17주식회사 유틸렉스Anti-TIGIT Antibody and Use Thereof
AU2022267219A1 (en)*2021-04-262023-10-05Memorial Hospital For Cancer And Allied DiseasesChimeric receptors targeting adgre2 and/or clec12a and uses thereof
CN117916263B (en)*2021-05-102025-04-25美帝马布生物公司Anti-TIGIT antibodies and uses thereof
JP2024527049A (en)2021-07-282024-07-19ジェネンテック, インコーポレイテッド Methods and Compositions for Treating Cancer
CA3228504A1 (en)*2021-08-092023-02-16Tianhang ZHAIAnti-tigit antibody and use thereof
WO2023056403A1 (en)2021-09-302023-04-06Genentech, Inc.Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
WO2023108609A1 (en)*2021-12-172023-06-22Shanghai Nigene Biological Science And Technology Co., Ltd.Tigit antibodies and uses thereof
CN120590537A (en)*2021-12-312025-09-05南京维立志博生物科技股份有限公司Bispecific antibodies targeting TIGIT
KR20240144422A (en)2022-03-152024-10-02컴퓨젠 엘티디. IL-18BP antagonist antibodies and their uses in monotherapy and combination therapy for cancer treatment
KR20250006959A (en)2022-05-022025-01-13아르커스 바이오사이언시즈 인코포레이티드 Anti-TIGIT antibodies and uses thereof
KR20250022049A (en)2022-06-072025-02-14제넨테크, 인크. Method for determining the efficacy of a treatment for lung cancer comprising an anti-PD-L1 antagonist and an anti-TIGIT antagonist antibody
TW202515608A (en)2023-06-262025-04-16以色列商坎布根有限公司Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
EP0154316B1 (en)1984-03-061989-09-13Takeda Chemical Industries, Ltd.Chemically modified lymphokine and production thereof
US4737456A (en)1985-05-091988-04-12Syntex (U.S.A.) Inc.Reducing interference in ligand-receptor binding assays
US5677425A (en)1987-09-041997-10-14Celltech Therapeutics LimitedRecombinant antibody
DE68925966T2 (en)1988-12-221996-08-29Kirin Amgen Inc CHEMICALLY MODIFIED GRANULOCYTE COLONY EXCITING FACTOR
GB9108652D0 (en)1991-04-231991-06-12Antisoma LtdImmunoreactive compounds
EP0604580A1 (en)1991-09-191994-07-06Genentech, Inc.EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
ES2191016T3 (en)1992-09-162003-09-01Scripps Research Inst HUMAN NEUTRALIZING MONOCLONAL ANTIBODIES FOR THE SYNCTIAL RESPIRATORY VIRUS.
JP3919830B2 (en)1992-11-282007-05-30財団法人化学及血清療法研究所 Anti-feline herpesvirus-1 recombinant antibody and gene fragment encoding the antibody
WO1995018634A1 (en)1994-01-041995-07-13The Scripps Research InstituteHuman monoclonal antibodies to herpes simplex virus and methods therefor
US5789199A (en)1994-11-031998-08-04Genentech, Inc.Process for bacterial production of polypeptides
US5840523A (en)1995-03-011998-11-24Genetech, Inc.Methods and compositions for secretion of heterologous polypeptides
US6267958B1 (en)1995-07-272001-07-31Genentech, Inc.Protein formulation
US6090382A (en)1996-02-092000-07-18Basf AktiengesellschaftHuman antibodies that bind human TNFα
US6171586B1 (en)1997-06-132001-01-09Genentech, Inc.Antibody formulation
US6194551B1 (en)1998-04-022001-02-27Genentech, Inc.Polypeptide variants
ES2292236T3 (en)1998-04-022008-03-01Genentech, Inc. VARIATIONS OF ANTIBODIES AND THEIR FRAGMENTS.
GB9814383D0 (en)1998-07-021998-09-02Cambridge Antibody TechImprovements relating to antibodies
CN101088561A (en)1998-07-212007-12-19展马博联合股份有限公司 Anti-hepatitis C virus antibody and use thereof
US6914128B1 (en)1999-03-252005-07-05Abbott Gmbh & Co. KgHuman antibodies that bind human IL-12 and methods for producing
US6818216B2 (en)2000-11-282004-11-16Medimmune, Inc.Anti-RSV antibodies
SE526864C2 (en)2004-07-052005-11-15Svensk Roekgasenergi Intressen Process and apparatus for separating pollutants from a gas stream
JO3000B1 (en)2004-10-202016-09-05Genentech IncAntibody Formulations.
WO2006124667A2 (en)2005-05-122006-11-23Zymogenetics, Inc.Compositions and methods for modulating immune responses
JP5933894B2 (en)2007-09-142016-06-15アディマブ, エルエルシー Rationally designed synthetic antibody libraries and their use
US8877688B2 (en)2007-09-142014-11-04Adimab, LlcRationally designed, synthetic antibody libraries and uses therefor
US8227577B2 (en)2007-12-212012-07-24Hoffman-La Roche Inc.Bivalent, bispecific antibodies
US9266967B2 (en)2007-12-212016-02-23Hoffmann-La Roche, Inc.Bivalent, bispecific antibodies
US8242247B2 (en)2007-12-212012-08-14Hoffmann-La Roche Inc.Bivalent, bispecific antibodies
US20090162359A1 (en)2007-12-212009-06-25Christian KleinBivalent, bispecific antibodies
EP2414391B1 (en)2009-04-022018-11-28Roche Glycart AGMultispecific antibodies comprising full length antibodies and single chain fab fragments
PT2417156E (en)2009-04-072015-04-29Roche Glycart AgTrivalent, bispecific antibodies
ES2439802T3 (en)2009-05-272014-01-24F. Hoffmann-La Roche Ag Tri- or tetra-specific antibodies
US9676845B2 (en)2009-06-162017-06-13Hoffmann-La Roche, Inc.Bispecific antigen binding proteins
US8703132B2 (en)2009-06-182014-04-22Hoffmann-La Roche, Inc.Bispecific, tetravalent antigen binding proteins
AU2011279073B2 (en)2010-07-162016-06-09Adimab, LlcAntibody libraries
HRP20201404T1 (en)2013-07-162020-11-27F. Hoffmann - La Roche Ag PROCEDURES FOR THE TREATMENT OF CANCER USING PD-1 BASIC BINDING ANTAGONIST AND TIGIT INHIBITOR
LT3126394T (en)2014-03-312020-01-27F. Hoffmann-La Roche AgAnti-ox40 antibodies and methods of use
MD4733C1 (en)*2014-08-192021-07-31Merck Sharp & Dohme Corp Anti-TIGIT antibodies
KR102644115B1 (en)*2014-12-232024-03-05브리스톨-마이어스 스큅 컴퍼니Antibodies to tigit
TWI715587B (en)*2015-05-282021-01-11美商安可美德藥物股份有限公司Tigit-binding agents and uses thereof
WO2017024465A1 (en)2015-08-102017-02-16Innovent Biologics (Suzhou) Co., Ltd.Pd-1 antibodies
AU2016307845B2 (en)*2015-08-142020-10-15Merck Sharp & Dohme LlcAnti-TIGIT antibodies
CN108137691B (en)2015-09-022021-10-19耶路撒冷希伯来大学伊萨姆研究发展有限公司Antibodies specific for human T-cell immunoglobulin and ITIM domain (TIGIT)
TWI811892B (en)*2015-09-252023-08-11美商建南德克公司Anti-tigit antibodies and methods of use
DK3356413T3 (en)2015-10-012022-04-11Potenza Therapeutics Inc ANTI-TIGIT ANTIGEN BINDING PROTEINS AND METHODS FOR USING IT
WO2017132827A1 (en)2016-02-022017-08-10Innovent Biologics (Suzhou) Co., Ltd.Pd-1 antibodies
IL261188B (en)2016-03-042022-08-01Jn Biosciences Llc An anti-tigit antibody that binds to the tigit polypeptide on one or more amino acid residues

Also Published As

Publication numberPublication date
US11370837B2 (en)2022-06-28
JP2024063083A (en)2024-05-10
KR20210040827A (en)2021-04-14
AU2019310803B2 (en)2022-11-03
JP2021532058A (en)2021-11-25
US20210040201A1 (en)2021-02-11
AU2019310803A1 (en)2020-09-17
CN112135626A (en)2020-12-25
CA3092456A1 (en)2020-01-30
BR112021001201A2 (en)2021-04-27
TW202019465A (en)2020-06-01
JP7524065B2 (en)2024-07-29
WO2020020281A1 (en)2020-01-30
CA3092456C (en)2024-03-12
CN112135626B (en)2023-05-23
EP3838289A1 (en)2021-06-23
ZA202100676B (en)2023-10-25
EP3838289A4 (en)2022-08-03
TWI754157B (en)2022-02-01

Similar Documents

PublicationPublication DateTitle
ZA202006904B (en)Anti-il-4r antibody and use thereof
SG11202100746WA (en)Anti-tigit antibody and use thereof
IL276950A (en)Anti-cd73 antibodies and uses thereof
IL268206A (en)Bcma-targeting antibody and use thereof
IL282968A (en)Anti-nkg2a antibodies and uses thereof
ZA202006066B (en)Anti-hla-g antibodies and use thereof
SG11202104240TA (en)Cll1-targeting antibody and application thereof
SG11202105885WA (en)Anti-claudin antibodies and uses thereof
IL275826A (en)Anti-mct1 antibodies and uses thereof
SG11202009772PA (en)Anti-dll3 antibodies and uses thereof
IL287690A (en)Anti-hvem antibodies and use thereof
ZA202006255B (en)Anti-pd-l1 antibody and use thereof
IL281297A (en)Anti-npr1 antibodies and uses thereof
IL281202A (en)Anti-tnfrsf9 antibodies and uses thereof
SG11202009625WA (en)Anti-trem-1 antibodies and uses thereof
IL280321A (en)Anti-cxcr2 antibodies and uses thereof
IL277075A (en)Anti-phf-tau antibodies and uses thereof
IL282707A (en)Anti-tim-3 antibodies and their use
IL282708A (en)Anti-tim-3 antibodies and their use
IL283875A (en)Anti-il-27 antibodies and uses thereof
IL277330A (en)Anti-il-27 antibodies and uses thereof
SG11202012680TA (en)Anti-l1cam antibodies and uses thereof
SG11202003585VA (en)Anti-vista antibody and use thereof
IL276548A (en)Bcma-binding antibodies and uses thereof
ZA201906248B (en)Anti-ceacam1 antibody and use thereof

[8]ページ先頭

©2009-2025 Movatter.jp